Drug-eluting stents in vascular intervention
暂无分享,去创建一个
[1] A. Yeung,et al. Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial , 2002, The Lancet.
[2] P. D. de Feyter,et al. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coro , 1999, Journal of the American College of Cardiology.
[3] S. Silber,et al. Rotational Atherectomy Does Not Reduce Recurrent In-Stent Restenosis Results of the Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial (ARTIST) , 2002 .
[4] P. Serruys,et al. Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation: Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up , 2002, Circulation.
[5] B. Davis,et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial , 2002, Circulation.
[6] M. Bennett,et al. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. , 2001, Pharmacology & therapeutics.
[7] P. Teirstein,et al. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. , 1999, Circulation.
[8] A. Grüntzig. TRANSLUMINAL DILATATION OF CORONARY-ARTERY STENOSIS , 1978, The Lancet.
[9] Elazer R. Edelman,et al. Drug-Eluting Stents in Preclinical Studies: Recommended Evaluation From a Consensus Group , 2002, Circulation.
[10] V. Fuster,et al. Viewpoint Overcoming restenosis with sirolimus: from alphabet soup to clinical reality , 2002, The Lancet.
[11] W Rutsch,et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.
[12] P. Teirstein,et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. , 2001, The New England journal of medicine.
[13] G. Papandreou,et al. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent , 2002, Coronary artery disease.
[14] C. Di Mario,et al. First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic Outcome , 2002, Circulation.
[15] J. Kjekshus,et al. Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. , 2001, Journal of the American College of Cardiology.
[16] P. Teirstein,et al. Five-Year Clinical Follow-Up After Intracoronary Radiation: Results of a Randomized Clinical Trial , 2002, Circulation.
[17] P. Serruys,et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.
[18] Renu Virmani,et al. Morphological Predictors of Restenosis After Coronary Stenting in Humans , 2002, Circulation.
[19] Antonio Colombo,et al. Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in Humans , 2002, Circulation.
[20] R. Califf,et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial , 1999, The Lancet.